Infinity BiologiX (IBX), which previously operated as RUCDR Infinite Biologics before spinning off from Rutgers University-New Brunswick in August 2020, announced on June 9 the launch of a new test meant to assess the severity of COVID-19 in individuals.
The COVID-19 Risk Test is designed to predict disease severity in people ages 18 and older, using genetic and clinical information to provide a risk score–individuals can then use that score to understand their personal risk of contracting a serious case of COVID-19 and make more informed decisions.
In addition, employers, governments and other public health entities may use the data to make informed decisions about disease risk, treatment options and vaccination priorities. This will assist in guiding proactive steps to minimize disease exposure and manage the pandemic in the weeks and months ahead.
The availability of the test in the U.S. is a collaboration with NASDAQ-listed Genetic Technologies Ltd. (GENE), Vault Health and IBX.
Developed by GENE, the test will be distributed and sold in the U.S. by Vault Health, released under GENE’s “powered by GeneType” brand. IBX will determine sales and end consumer pricing structure for the risk test and will produce, distribute and market in the U.S.
“We see this initial agreement for the sale and distribution of Genetic Technologies’ COVID-19 Risk Test as a critical collaboration in line with our mission to understand the genetic causes of common, complex diseases and to discover diagnoses, treatments and, eventually, cures for these diseases,” Robin Grimwood, IBX chief executive officer, explained in a prepared statement.
Extensive experience with large-scale COVID-19 testing and sample processing made IBX a clear choice for this endeavor. Through its labs in New Jersey and Minnesota, IBX, along with its partner organizations around the U.S., is able to process over 100,000 risk tests per day.
In May 2020 IBX launched and received U.S. Food and Drug Administration Emergency Use Authorization for the first saliva-based COVID-19 test, performed at home through Vault Health’s end-to-end telehealth platform.